Department of Medical Sciences, University of Guanajuato, Leon, Mexico.
J Clin Periodontol. 2010 Nov;37(11):1016-22. doi: 10.1111/j.1600-051X.2010.01619.x. Epub 2010 Sep 5.
We studied the effect of atorvastatin (ATV) treatment on bone loss prevention in subjects with chronic periodontitis.
In this controlled double-blind study, 38 subjects with chronic periodontitis were randomized into two groups, paired by age to receive ATV (20 mg) or placebo daily for 3 months. Periodontal mechanical treatment was carried out in both groups at baseline. Clinical and radiographic parameters and bone turnover markers were assessed at baseline and at 3 months.
Periodontal disease conditions improved in both groups. After comparing the figures of change, significant improvements were observed in cholesterol levels (Δ=-58.5 ± 37.6 versusΔ=5.4 ± 41.2 mg/dl, p<0.0002), low-density lipoprotein levels (Δ=-48.1 ± 31.7 versusΔ=1.9 ± 42.8 mg/dl, p<0.002), dental mobility (Δ=-0.17 ± 0.11 versusΔ=-0.06 ± 0.11%, p<0.04), and the distance from the crestal alveolar bone to the cemento-enamel junction (Δ=-0.75 ± 0.7 versusΔ=0.09 ± 0.4 mm, p<0.0006) in the ATV group.
The results suggest that ATV might have beneficial effects on bone alveolar loss and tooth mobility in subjects with periodontal disease.
我们研究了阿托伐他汀（ATV）治疗对慢性牙周炎患者预防骨丢失的影响。
在这项对照双盲研究中，38 名慢性牙周炎患者按年龄配对分为两组，分别接受每日 ATV（20mg）或安慰剂治疗 3 个月。两组患者在基线时均接受牙周机械治疗。在基线和 3 个月时评估临床和影像学参数以及骨转换标志物。
两组的牙周病状况均有所改善。比较变化数值后，胆固醇水平（Δ=-58.5±37.6 与Δ=5.4±41.2mg/dl，p<0.0002）、低密度脂蛋白水平（Δ=-48.1±31.7 与Δ=1.9±42.8mg/dl，p<0.002）、牙齿松动度（Δ=-0.17±0.11 与Δ=-0.06±0.11%，p<0.04）和牙槽骨顶至牙釉质牙骨质界的距离（Δ=-0.75±0.7 与Δ=0.09±0.4mm，p<0.0006）在 ATV 组均有显著改善。
结果表明，阿托伐他汀可能对牙周病患者的牙槽骨丢失和牙齿松动有有益作用。
